Tom Powles on RCC patients receiving ICI therapy
Tom Powles shared on X:
“During the period of PD-1 inhibition availability for RCC in the UK only 60% of patients with progressive renal cancers (n>1000) received ICI therapy(1st-3rd line).
This occurred across IMDC risk groups.
Assuming all patients will eventually receive ICI is not supported by data.”
Source: Tom Powles/X
Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre.
With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.